Randy Teel, Ph.D. , has served as our President and Chief Executive Officer and as a member of our board of directors since February 2026. Dr. Teel joined Arvinas in 2018 and has 20 years of biopharmaceutical industry experience. Dr. Teel served as our Chief Business Officer from April 2024 to February 2026, and in that role was responsible for corporate strategy, business development, corporate communications, and investor relations. From February 2024 to June 2024, Dr. Teel also served as our interim Chief Financial Officer, Treasurer and principal financial officer, while we undertook a search to identify our next permanent Chief Financial Officer, Treasurer and principal financial officer. From September 2021 to April 2024, Dr. Teel served as our Senior Vice President, Corporate and Business Development. From May 2018 to September 2021, Dr. Teel served as our Vice President of Corporate Development. Prior to Arvinas, from March 2017 to December 2017, Dr. Teel was Vice President and Head of Strategy at Alexion Pharmaceuticals, a biotechnology company, or Alexion, where he was responsible for long-range planning, partnering with the research and development and commercial organizations as they developed inline and lifecycle management strategies, and from March 2015 to March 2017, he was Executive Director, Corporate Strategy and Enterprise Risk Management at Alexion. From January 2008 to March 2015, Dr. Teel was a consultant at McKinsey & Company, a global management consulting firm, where he advised biopharmaceutical clients on issues in commercial, medical, and development. Dr. Teel received his B.Sc. in Biology at Gonzaga University and his Ph.D. in Immunobiology from Yale University. We believe Dr. Teel is qualified to serve on our board of directors due to his extensive executive leadership experience at life sciences companies and his historical experience gained from serving in various roles with us.